


**Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one, ~~wherein it contains, comprising,~~ as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof in an aqueous base;

a percutaneous absorption accelerator selected from the group consisting of oleyl alcohol, lauryl alcohol, cetyl alcohol, crotamiton, and cyclodextrin;  
a reaction speed adjuster selected from the group consisting of citric acid, lactic acid, and tartaric acid; and

a dissolving agent selected from the group consisting of N-methyl-2-pyrrolidone, macrogol, isopropanol, metha oil, butylenes glycol, oleyl alcohol, and isopropyl myristate,

wherein the aqueous base comprises:

a water-soluble polymer selected from the group consisting of sodium polyacrylate, ~~starch acrylate~~<sup>starch acrylate</sup>, and methyl acrylate/acrylic acid 2-ethylhexyl copolymer resin emulsion;


a cross-linking agent; agent selected from the group consisting of aluminum hydroxide, and magnesium aluminum hydroxide; and  
a polyhydric alcohol selected from the group consisting of ethylene glycol, propylene glycol, trimethylene glycol, and glycerin; and  
water.

2. (Canceled)

3. (Previously Presented) The percutaneous absorption preparation according to claim 1, wherein the aqueous base contains, based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.

4-5. (Canceled)

6. (Currently Amended) A percutaneous absorption adhesive preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one, wherein a support medium, a base layer formed of an aqueous base containing, as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof, and a liner are sequentially laminated and formed, wherein the aqueous base comprises:

a water-soluble polymer selected from the group consisting of sodium polyacrylate, starch acrylate, and methyl acrylate/acrylic acid 2-ethylhexyl copolymer resin

~~emulsion polyacrylamide, polyethylene imine, carboxy vinyl polymer, starch acrylate, ethyl vinyl acetate, and starch;~~

a cross-linking agent selected from the group consisting of aluminum hydroxide, and magnesium aluminum hydroxide;

a polyhydric alcohol selected from the group consisting of ethylene glycol, propylene glycol, trimethylene glycol, and glycerin; and

water.

7. (Cancelled)

8. (Previously Presented) The percutaneous absorption adhesive preparation according to claim 6, wherein the aqueous base contains, based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.

9-10. (Cancelled)

11. (Previously Presented) The percutaneous absorption adhesive preparation according to claim 1, wherein the preparation is used for treating arteriosclerosis, hepatic damage, retinal damage, diabetes or gastrointestinal mucous membrane damage.

12. (Cancelled)

13. (Previously Presented) The percutaneous absorption preparation according to claim 1, wherein the cross-linking agent is aluminum hydroxide.

14. (Previously Presented) The percutaneous absorption preparation according to claim 1, wherein the polyhydric alcohol is glycerin.

15. (Previously Presented) The percutaneous absorption preparation according to claim 1, further comprising N-methyl-2-pyrrolidone as a dissolving agent.

16. (Previously Presented) The percutaneous absorption preparation according to claim 1, further comprising crotamiton as a percutaneous absorption accelerator.

17. (Currently Amended) The percutaneous absorption preparation according to claim 1, further comprising ~~tartatic~~-tartaric acid as a speed adjuster.

18. (New) The percutaneous absorption preparation according to claim 1, further comprising talc, wherein the percutaneous absorption accelerator is crotamiton;  
the reaction speed adjuster is tartaric acid;  
the dissolving agent is N-methyl-2-pyrrolidone;  
the water-soluble polymer is a combination of sodium polyacrylate, starch acrylate and methyl acrylate/acrylic acid 2-ethylhexyl copolymer resin emulsion;  
the cross-linking agent is aluminum hydroxide; and  
the polyhydric alcohol is glycerin.